Drug Profile
Research programme: encapsulated methionine gamma lyase - PHAXIAM Therapeutics
Alternative Names: ERY-MET; Erymet; Erymethionase programme; Erymethionase therapeutics - PHAXIAM Therapeutics; erythrocyte encapsulated methionine γ lyase; ERYZYMELatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator ERYtech Pharma
- Developer Fox Chase Cancer Center; PHAXIAM Therapeutics
- Class Antineoplastics; Carbon sulfur lyases
- Mechanism of Action Amino acid modulators; Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Homocystinuria
Most Recent Events
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 28 Apr 2021 No recent reports of development identified for preclinical development in Homocystinuria in France (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in France (IV, Injection)